Suncadia Biopharmaceuticals

Suncadia Biopharmaceuticals is a clinical-stage biopharmaceutical company based in China, operating as a specialized subsidiary of Jiangsu Hengrui Pharmaceuticals. The company focuses on the discovery and development of innovative oncology therapeutics, particularly in the fields of immunotherapy and targeted biologics. Suncadia manages a robust pipeline that includes PD-1 inhibitors, bispecific antibodies, and antibody-drug conjugates (ADCs) aimed at treating various solid tumors. By leveraging the extensive R&D infrastructure of its parent company, Suncadia has successfully advanced multiple candidates through clinical trials and into the commercial market in China. Their mission is to provide high-quality, affordable innovative medicines to patients globally, with a primary focus on high-incidence cancers.